Successful marrow transplantation for acute myelocytic leukemia following therapy for Hodgkin's disease

R. B. Geller, Georgia Boyce Vogelsang, J. R. Wingard, A. M. Yeager, W. H. Burns, G. W. Santos, R. Saral

Research output: Contribution to journalArticle

Abstract

Five patients with acute myelocytic leukemia (AML) after combined modality therapy for Hodgkin's disease (HD) were treated with cyclophosphamide and busulfan followed by bone marrow transplantation (BMT). Four patients received allogeneic transplants from histocompatibility locus antigen (HLA)-compatible siblings and the fifth patient received an autologous marrow treated with 4-hydroperoxycyclophosphamide. Two patients died of complications of acute graft-v-host disease (GVHD) despite prophylaxis with either low-dose cyclophosphamide or cyclosporine. The remaining three patients were alive and disease-free 382, 617, and 620 days after transplant. These initial results are encouraging and more patients with treatment-related AML need to be evaluated with both allogeneic and autologous BMT to fully elucidate the potentially curative role of this intensive therapy in an otherwise fatal hematologic malignancy.

Original languageEnglish (US)
Pages (from-to)1558-1561
Number of pages4
JournalJournal of Clinical Oncology
Volume6
Issue number10
StatePublished - 1988

Fingerprint

Hodgkin Disease
Acute Myeloid Leukemia
Transplantation
Bone Marrow
perfosfamide
Bone Marrow Transplantation
Transplants
Cyclophosphamide
Therapeutics
Busulfan
Combined Modality Therapy
Histocompatibility Antigens
Autologous Transplantation
Hematologic Neoplasms
Cyclosporine
Siblings

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Geller, R. B., Vogelsang, G. B., Wingard, J. R., Yeager, A. M., Burns, W. H., Santos, G. W., & Saral, R. (1988). Successful marrow transplantation for acute myelocytic leukemia following therapy for Hodgkin's disease. Journal of Clinical Oncology, 6(10), 1558-1561.

Successful marrow transplantation for acute myelocytic leukemia following therapy for Hodgkin's disease. / Geller, R. B.; Vogelsang, Georgia Boyce; Wingard, J. R.; Yeager, A. M.; Burns, W. H.; Santos, G. W.; Saral, R.

In: Journal of Clinical Oncology, Vol. 6, No. 10, 1988, p. 1558-1561.

Research output: Contribution to journalArticle

Geller, RB, Vogelsang, GB, Wingard, JR, Yeager, AM, Burns, WH, Santos, GW & Saral, R 1988, 'Successful marrow transplantation for acute myelocytic leukemia following therapy for Hodgkin's disease', Journal of Clinical Oncology, vol. 6, no. 10, pp. 1558-1561.
Geller, R. B. ; Vogelsang, Georgia Boyce ; Wingard, J. R. ; Yeager, A. M. ; Burns, W. H. ; Santos, G. W. ; Saral, R. / Successful marrow transplantation for acute myelocytic leukemia following therapy for Hodgkin's disease. In: Journal of Clinical Oncology. 1988 ; Vol. 6, No. 10. pp. 1558-1561.
@article{ccbe1f72348b495dad71ee0f26a7daa5,
title = "Successful marrow transplantation for acute myelocytic leukemia following therapy for Hodgkin's disease",
abstract = "Five patients with acute myelocytic leukemia (AML) after combined modality therapy for Hodgkin's disease (HD) were treated with cyclophosphamide and busulfan followed by bone marrow transplantation (BMT). Four patients received allogeneic transplants from histocompatibility locus antigen (HLA)-compatible siblings and the fifth patient received an autologous marrow treated with 4-hydroperoxycyclophosphamide. Two patients died of complications of acute graft-v-host disease (GVHD) despite prophylaxis with either low-dose cyclophosphamide or cyclosporine. The remaining three patients were alive and disease-free 382, 617, and 620 days after transplant. These initial results are encouraging and more patients with treatment-related AML need to be evaluated with both allogeneic and autologous BMT to fully elucidate the potentially curative role of this intensive therapy in an otherwise fatal hematologic malignancy.",
author = "Geller, {R. B.} and Vogelsang, {Georgia Boyce} and Wingard, {J. R.} and Yeager, {A. M.} and Burns, {W. H.} and Santos, {G. W.} and R. Saral",
year = "1988",
language = "English (US)",
volume = "6",
pages = "1558--1561",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "10",

}

TY - JOUR

T1 - Successful marrow transplantation for acute myelocytic leukemia following therapy for Hodgkin's disease

AU - Geller, R. B.

AU - Vogelsang, Georgia Boyce

AU - Wingard, J. R.

AU - Yeager, A. M.

AU - Burns, W. H.

AU - Santos, G. W.

AU - Saral, R.

PY - 1988

Y1 - 1988

N2 - Five patients with acute myelocytic leukemia (AML) after combined modality therapy for Hodgkin's disease (HD) were treated with cyclophosphamide and busulfan followed by bone marrow transplantation (BMT). Four patients received allogeneic transplants from histocompatibility locus antigen (HLA)-compatible siblings and the fifth patient received an autologous marrow treated with 4-hydroperoxycyclophosphamide. Two patients died of complications of acute graft-v-host disease (GVHD) despite prophylaxis with either low-dose cyclophosphamide or cyclosporine. The remaining three patients were alive and disease-free 382, 617, and 620 days after transplant. These initial results are encouraging and more patients with treatment-related AML need to be evaluated with both allogeneic and autologous BMT to fully elucidate the potentially curative role of this intensive therapy in an otherwise fatal hematologic malignancy.

AB - Five patients with acute myelocytic leukemia (AML) after combined modality therapy for Hodgkin's disease (HD) were treated with cyclophosphamide and busulfan followed by bone marrow transplantation (BMT). Four patients received allogeneic transplants from histocompatibility locus antigen (HLA)-compatible siblings and the fifth patient received an autologous marrow treated with 4-hydroperoxycyclophosphamide. Two patients died of complications of acute graft-v-host disease (GVHD) despite prophylaxis with either low-dose cyclophosphamide or cyclosporine. The remaining three patients were alive and disease-free 382, 617, and 620 days after transplant. These initial results are encouraging and more patients with treatment-related AML need to be evaluated with both allogeneic and autologous BMT to fully elucidate the potentially curative role of this intensive therapy in an otherwise fatal hematologic malignancy.

UR - http://www.scopus.com/inward/record.url?scp=0024274274&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024274274&partnerID=8YFLogxK

M3 - Article

C2 - 3049950

AN - SCOPUS:0024274274

VL - 6

SP - 1558

EP - 1561

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 10

ER -